tag association-accessible-medicine 
pharmaphorum
NOVEMBER 19, 2021
Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the company. million price tag make it is the most expensive treatment ever approved for NHS funding.
Pharmaceutical Technology
JULY 14, 2022
Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The challenge of providing adequate access to the peripheral EU markets is quite evident. Europe’s forgotten territories.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 8, 2021
” Biogen meanwhile has been taking flak over its decision to price Aduhelm at $56,000 per year, which looks set to re-ignite debate in the US about the cost of medicines. AA provides earlier patient access to a promising treatment but requires sponsors to conduct an additional trial to verify benefit. billion in 2027.
pharmaphorum
JUNE 2, 2021
NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. Comments can be submitted until 23 June.
Pharmaceutical Technology
JUNE 29, 2022
Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications.
Pharmaceutical Technology
MAY 15, 2023
Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
pharmaphorum
AUGUST 28, 2020
Giving the Joseph Leiter lecture at this year’s virtual Medical Library Association (MLA) conference Harvard Medical School’s Professor John Brownstein spoke about embracing non-traditional data streams in public health. Many other industries have exploded because they’ve been able to access data,” he said. “If Data inadequacies.
Expert insights. Personalized for you.
98 
Let's personalize your content